Orion (271560.KS) Akcie Kurz
Orion Kurz
Tržby rostly o 14,7 % ročně za posledních 8 let na 3,32 Mld. KRW. Zisk na akcii rostl o 45,5 % ročně za posledních 8 let. čistá marže společnosti Orion je nyní 11,5 %, převážně stabilní z 11,0 % před několika lety. Orion aktuálně nabízí dividendový výnos kolem 2,14 %. Výplatní poměr je kolem 26 % zisku. Dividenda rostla o 19,5 % ročně za posledních 8 let. Medián cílové ceny analytiků je 142 800,00 KRW, tedy nad aktuální cenu o 22,4 %. Z 27 analytiků jich 23 doporučuje nákup — celkový konsenzus je Koupit.
Cena akcie Orion
Tato data přes Eulerpool API
100 000 požadavků/měs. zdarma · bez karty
Obchodní model Orion a analýza akcií
Nejčastější otázky týkající se akcie Orion
Orion Corp is primarily present in Finland and several other key international markets. The company has a strong presence not only in its home country but also in various regions across the globe. With a global footprint, Orion Corp operates in several countries and regions, including Europe, North America, Latin America, and Asia. The company's extensive geographical reach allows it to serve a diverse customer base and expand its business worldwide.
The business model of Orion Corp focuses on the development, production, and marketing of pharmaceuticals and active pharmaceutical ingredients (APIs). Orion Corp is a renowned company known for its expertise in the field of neurological medicines, especially Parkinson's disease and Alzheimer's disease. With a strong emphasis on research and development, Orion Corp offers a wide range of prescription drugs, including branded and generic medications to serve patients globally. By combining scientific innovation with a commitment to improving patient well-being, Orion Corp continues to shape the future of healthcare with its pharmaceutical solutions.
Orion Corp is primarily active in the pharmaceutical and healthcare industries.
Orion Corp, a renowned company in the stock market, faces tough competition from several key players in its industry. Some of Orion Corp's main competitors include ABC Inc., XYZ Corporation, and DEF Ltd. These competitors are also highly regarded within the market and offer similar products or services as Orion Corp. However, Orion Corp has managed to maintain its strong market position by consistently delivering innovative solutions, exceptional customer service, and an unwavering commitment to quality. Despite the competition, Orion Corp continues to thrive and stand out among its rivals through its unique offerings and strategic business approach.
Orion Corp is a renowned company in the healthcare industry. Founded in 1917, Orion Corp has a rich history of providing innovative pharmaceutical and diagnostic products. Over the years, the company has expanded its portfolio and established itself as a global leader in various therapeutic areas, including neurology, oncology, and respiratory diseases. With a strong focus on research and development, Orion Corp continually strives to develop groundbreaking treatments that improve patients' lives. Leveraging its expertise and global presence, the company aims to address unmet medical needs and contribute to advancing healthcare worldwide.
Orion Corp has accomplished several significant milestones throughout its history. From its establishment in 1917, the company has continuously expanded its portfolio in pharmaceuticals and diagnostics. With a strong focus on research and development, Orion Corp has successfully introduced innovative treatments and medications to the market. Some notable achievements include the launch of Stalevo, a Parkinson's disease medication, and Simdax, a treatment for acute decompensated heart failure. Moreover, the company has received numerous awards and recognitions for its contributions to the healthcare industry. Orion Corp's dedication to delivering high-quality healthcare solutions has established its position as a renowned and trusted pharmaceutical company in the market.
Orion Corp is a leading company that upholds strong values and a transparent corporate philosophy. With a focus on innovation, quality, and sustainability, Orion Corp aims to provide unparalleled products and services to its customers. The company prioritizes ethical practices, integrity, and social responsibility, striving to make a positive impact on the community and the environment. By incorporating cutting-edge technologies and forward-thinking strategies, Orion Corp remains committed to achieving excellence in its business operations. Through continuous growth and a customer-centric approach, Orion Corp continues to be a trusted and reliable choice in the market.
Analytici aktuálně stanovují průměrnou cílovou cenu 142 200,00 KRW pro akcii Orion (medián: 142 800,00 KRW), tedy +21,9 % vůči poslední ceně. Konsensus vychází z 27 hodnocení analytiků.
27 analytiků aktuálně hodnotí akcii Orion: 23 doporučuje koupit, 4 držet a 0 prodat. Pro rok 2026 analytici očekávají u Orion tržby 3,77 Mld. KRW a zisk na akcii 11 919,85 KRW.
Při aktuálním kurzu se akcie Orion obchoduje za 77,40 EUR (116 700,00 KRW).
Akcie Orion (271560.KS) je kótována na 1 burzách, mimo jiné: KOSPI (Seoul) (271560.KS).
Orion Corporation is a Finnish pharmaceutical company specialized in the development, manufacturing, and marketing of medicinal drugs. The company operates in multiple industries, including the pharmaceutical industry, machinery, and diagnostics. Its main business areas are human pharmaceuticals, animal health, and diagnostics. Orion offers a wide range of drugs for the treatment and prevention of various diseases, specializing in neurological, cardiovascular, urological, cancer, and infectious diseases. The company also produces and distributes pharmaceutical products for animals, as well as diagnostic products for disease detection. In addition, Orion is involved in the production of pharmaceutical machinery such as tablet presses and mixers. The company has a research and development department focused on developing new drugs and technologies, investing continuously in research to improve product quality and acquire valuable patents. Some of Orion's key products include therapies for Parkinson's disease, such as Stalevo and Comtess, and the prostate cancer medication, Xtandi. Orion distributes its products globally and has branches in Europe, Asia, and North America. In summary, Orion's business model revolves around the development, manufacturing, and marketing of a wide range of pharmaceutical products. It operates in multiple industries and has a research and development department dedicated to innovation.
Tržby očekávané za Orion činí 3,77 Mld. KRW. Tato hodnota je založena na aktuálních finančních údajích a odráží výkonnost společnosti.
Zisk očekávané za Orion činí 471,18 Mld. KRW. Čistý zisk odráží ziskovost společnosti po odečtení všech nákladů.
Poměr ceny k zisku (P/E) Orion je aktuálně 9,79. Poměr P/E porovnává aktuální cenu akcie se ziskem na akcii a pomáhá investorům posoudit ocenění akcie Orion.
Poměr ceny k tržbám (P/S) Orion je aktuálně 1,22. Poměr P/S porovnává tržní kapitalizaci s ročními tržbami a slouží jako metrika ocenění akcie Orion.
Score kvality pro Orion je 4/10.
ISIN Orion je KR7271560005. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.
Ticker Orion je 271560.KS. Symbol tickeru se používá k obchodování akcií Orion na burze.
Orion akcie
Orion Peer Group
Orion Ticker
Orion FIGI
Všechny fundamentální údaje o Orion v podrobné analýze
Naše analýzy akcií společnosti Orion zahrnují důležité finanční ukazatele jako obrat, zisk, P/E poměr, P/S poměr, EBIT, stejně jako informace o dividendách. Dále zkoumáme aspekty jako akcie, tržní kapitalizaci, dluhy, vlastní kapitál a závazky společnosti Orion. Pokud hledáte podrobnější informace o těchto tématech, nabízíme vám na našich podstránkách rozsáhlé analýzy: